Literature DB >> 18216583

Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis.

George D Kymionis1, David Goldman, Takeshi Ide, Sonia H Yoo.   

Abstract

PURPOSE: To report a case of refractory giant papillary conjunctivitis (GPC) treated by using topical tacrolimus 0.03% ointment.
METHODS: A 16-year-old white boy with a history of GPC was referred to our department for severe GPC with eye itching, tearing, photophobia, discharge, and blepharospasm. The patient had received previous treatments with antihistamines, mast cell stabilizers, topical corticosteroid ointments, and surgical resection-cryopexy of GPC that were ineffective.
RESULTS: Topical tacrolimus 0.03% ointment (Protopic; 0.5 cm) was applied into the lower fornix twice a day. An improvement of the patient's symptoms was observed during the first 5 days of therapy, and the GPC was resolved within 15 days. After 1 month of continued topical tacrolimus ointment treatment, there was no evidence of GPC. Topical tacrolimus was tapered during the next 2 months. Six months after treatment, there were no GPC findings, and no side effects were reported.
CONCLUSIONS: Topical tacrolimus 0.03% ointment for severe GPC, refractory to conventional therapy, appears to be an effective alternative treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18216583     DOI: 10.1097/ICO.0b013e318159afbb

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  13 in total

Review 1.  Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis.

Authors:  Pakit Vichyanond; Panida Kosrirukvongs
Journal:  Curr Allergy Asthma Rep       Date:  2013-06       Impact factor: 4.806

2.  A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.

Authors:  Yuichi Ohashi; Nobuyuki Ebihara; Hiroshi Fujishima; Atsuki Fukushima; Naoki Kumagai; Yayoi Nakagawa; Kenichi Namba; Shigeki Okamoto; Jun Shoji; Etsuko Takamura; Kunihiko Hayashi
Journal:  J Ocul Pharmacol Ther       Date:  2010-04       Impact factor: 2.671

3.  Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis.

Authors:  A Kheirkhah; M K Zavareh; F Farzbod; M Mahbod; M J Behrouz
Journal:  Eye (Lond)       Date:  2011-04-08       Impact factor: 3.775

4.  Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis.

Authors:  Ajit Kumar Hazarika; Prodip Kumar Singh
Journal:  J Nat Sci Biol Med       Date:  2015-08

5.  Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis.

Authors:  Samir S Shoughy; Mahmoud O Jaroudi; Khalid F Tabbara
Journal:  Clin Ophthalmol       Date:  2016-04-07

Review 6.  Topical tacrolimus in anterior segment inflammatory disorders.

Authors:  Samir S Shoughy
Journal:  Eye Vis (Lond)       Date:  2017-03-09

7.  Comparison of the safety and efficacy of topical Tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis.

Authors:  Rahul Bhargava; Prachi Kumar
Journal:  Indian J Ophthalmol       Date:  2019-05       Impact factor: 1.848

8.  The use of topical tacrolimus 0.1% skin ointment for anterior segment conditions: a case series.

Authors:  Poorna Abeysiri; Nicholas R Johnston; Anthony C B Molteno
Journal:  Ophthalmol Eye Dis       Date:  2010-02-23

9.  Tacrolimus Ointment for Treatment of Vernal Keratoconjunctivitis.

Authors:  Abdulrahman M Al-Amri; Aleem Gulzar Mirza; Ahmed Mossa Al-Hakami
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Jan-Mar

10.  Long-term use of 0.003% tacrolimus suspension for treatment of vernal keratoconjunctivitis.

Authors:  Abdulrahman Mohammed Al-Amri; Sandra Flavia Fiorentini; Maan A Albarry; Ashjan Yousef Bamahfouz
Journal:  Oman J Ophthalmol       Date:  2017 Sep-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.